Meet Our Board
Of Directors

Daniel Cohen Chairman of the Board

Chief Executive Officer of Pharmadrug since it went public in August of 2018. Prior to that, he worked in the Canadian Capital Markets for almost 20 years. Most recently, he was a Partner and Head of Sales at Beacon Securities.

David Kideckel, Director

David joins PharmaDrug after nearly 20 years of combined industry and capital markets experience, most recently serving as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets. David’s industry experience spans several senior healthcare & biotechnology executive roles including at Johnson & Johnson Inc. and Alexion Pharmaceuticals (acquired by AstraZeneca).

Robert Schwartz, Director

Principal and founder at Wa-Lin Trading from 2002 to present. Serial entrepreneur for over 15 years. His expertise lies in manufacturing, global supply and distribution chain management. His background is in financial services related to micro and small cap companies (life science and logistics) leading expansion and M&A.

Paul McClory, Director

Entrepreneur – an international businessman who has spent the majority of his career developing new technologies to market take-off.

Michael Forbes, Director

A pharmacist and entrepreneur who over the past 16 years has successfully built a chain of pharmacies throughout British Columbia and Alberta as well as founded a cannabis production facility, opened medical cannabis clinics, and cannabis production facilities.

Nikolai Vassev, Director

Entrepreneur and business executive with a strong track record of driving top line growth at disruptive technology companies. Nikolai is the founder and CEO of Mindleap Health Inc., the world’s first telemedicine platform focused on psychedelic treatments and is also a contributor to Forbes, Entrepreneur and other leading business publications.

Al Quong, Chair of Audit Committee

Chief Financial Officer for the Fovere Group of Companies, from 2011 to present.